PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22192465-1	2012	Chronic Levodopa (L-DOPA), the gold standard therapy for Parkinson"s disease (PD), causes disabling motor complications (dyskinesias) that are associated with changes in the activity of striatal protein kinase A (PKA) and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32).	Levodopa	8-16	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	263-271	
22449381-8	2012	In agreement with the behavioral analysis, 7-nitroindazole reduced the l-DOPA-induced increases in DeltaFosB, phospho-DARPP32 and phospho-GluA1 AMPA receptor subunit levels in the striatum of 6-hydroxydopamine-lesioned rats.	Levodopa	71-77	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	118-125	
22449381-2	2012	Previous studies using animal models show that repeated administration of l-DOPA results in alterations of some signaling molecules, including DeltaFosB, phospho-DARPP32 and phosoho-GluA1 (also referred to as GluR1 or GluR-A) AMPA receptor subunits.	Levodopa	74-80	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	162-169	
22192465-1	2012	Chronic Levodopa (L-DOPA), the gold standard therapy for Parkinson"s disease (PD), causes disabling motor complications (dyskinesias) that are associated with changes in the activity of striatal protein kinase A (PKA) and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32).	Levodopa	18-24	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	263-271	
16029214-7	2005	Levodopa administration reversed the increased phosphorylation of both CaMKIIalpha and DARPP-32.	Levodopa	0-8	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	87-95	
20060905-3	2010	Using the 6-hydroxydopamine-lesioned rat model of PD, we showed that l-DOPA elicits profound alterations in the activity of three LID molecular markers, namely DeltaFosB, dopamine, cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), as well as in phosphorylation levels of the cytoskeletal-associated protein tau.	Levodopa	69-75	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	222-230	
19118628-6	2009	Additionally, L-DOPA-induced elevations in striatal pre-proenkephalin-A (PPE-A) (but not PPE-B, phospho[Thr(34)]DARPP-32, D1, and D2 receptor mRNA or D3 receptor levels) were reduced in S33084 treated animals.	Levodopa	14-20	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	112-120	
19393228-7	2009	The chronic levodopa treatment upregulated the adenosine A(2A) receptor expression and modified downstream signaling pathway including decreasing the phosphorylation of DARPP-32 at Thr75 site and increasing the phosphorylation of ERK1/2 in the lesioned striatum.	Levodopa	12-20	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	169-177	
19393228-9	2009	Our results indicate that the inhibitory effect of CSC on levodopa-induced motor fluctuation may be associated with the inhibition of Adenosine A(2A) Receptor and downstream DARPP-32 and ERK1/2 signaling pathway.	Levodopa	58-66	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	174-182	
17884291-0	2007	Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.	Levodopa	111-117	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	37-45	
17884291-3	2007	Our data demonstrated significantly increased levels of PDyn mRNA and phospho-Thr-34 DARPP-32 and significantly decreased phospho-Thr-75 DARPP-32 in LID rats compared with control and l-dopa treated groups.	Levodopa	184-190	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	137-145	
7931332-5	1994	Moreover, the threonine phosphorylation of DARPP-32 produced by maximally effective doses of either forskolin (in striatum) or L-3,4-dihydroxyphenylalanine (in substantia nigra) was increased further by GABA.	Levodopa	127-155	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	43-51	
31491493-8	2019	Finally, overexpression of beta-arrestin2 diminished L-dopa-induced D1R and phosphor-DARPP32/ERK levels.	Levodopa	53-59	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	85-92	
34434108-5	2021	Moreover, the increases of dopamine D1-receptor, p-DARPP-32, DeltaFosB, p-ERK1/2, and p-c-Jun ser63, along with the decrease in p-c-Jun ser73, induced by L-dopa in 6-OHDA-treated rats were significantly reversed by pretreatment with CA.	Levodopa	154-160	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	51-59	
29093677-8	2017	Intermittent L-dopa administration enhanced the expression of membrane D1R, and induced a robust increase of phosphorylation of Shp-2, Src, DARPP-32, and ERK1/2 in the 6-OHDA-lesioned striatum.	Levodopa	13-19	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	140-148	
25395834-3	2014	L-DOPA has also been found to modify the two key signaling cascades, protein kinase A/dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), in striatal neurons, which are thought to play a pivotal role in forming motor complications.	Levodopa	0-6	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	141-149	
25395834-8	2014	Similarly, chronic injections of WIN-55,212-2 influence the L-DOPA-induced alteration of DARPP-32 and ERK1/2 phosphorylation status in striatal neurons.	Levodopa	60-66	protein phosphatase 1, regulatory (inhibitor) subunit 1B	Rattus norvegicus	89-97